The effect of weight loss on inflammation in obese women with polycystic ovary syndrome.
BACKGROUND
The aim of the present study was to evaluate the effect of modest weight reduction on serum concentrations of tumour necrosis factor alpha (TNF-alpha), TNF soluble receptors (sTNFRs) and interleukin-6 (IL-6) in obese women with polycystic ovary syndrome (PCOS).


METHODS
The study group consisted of 15 obese women with PCOS (mean age 28.5 +/- 7.7 years). Serum concentrations of TNF-alpha, sTNFRs and IL-6, insulin, FSH, LH, DHEAS, androstendione, total and free testosterone, cortisol, 17OH-progesterone, oestradiol and sex hormone binding globulin (SHBG), glucose, total cholesterol, HDL cholesterol and triglycerides were measured before treatment and after 10% weight loss. All patients were advised to follow a 1000-1200 kcal diet with a limited intake of simple carbohydrate and animal fats and to exercise regularly (30 min, 3 times a week). Body composition was measured by bioimpedance. Serum concentrations of TNF-alpha, sTNFRs and IL-6 were determined by enzyme linked immunosorbent assay (ELISA). Plasma insulin, FSH, LH, DHEAS, androstendione, total and free testosterone, cortisol, 17OH-progesterone, oestradiol and SHBG were measured by a commercial RIA. Blood glucose, total cholesterol, HDL cholesterol and triglycerides were measured by an enzymatic procedure.


RESULTS
We observed no differences in serum concentrations of TNF-alpha, sTNFRs or IL-6 after treatment.


CONCLUSIONS
It seems that more than a modest weight reduction is necessary to obtain a decrease in serum concentrations of proinflammatory cytokines and an improvement in ovarian function in obese women with polycystic ovary syndrome.
Olszanecka-Glinianowicz
Magdalena
M
Department of Pathophysiology, Medical University of Silesia, Katowice, Poland. magols@esculap.pl
Zahorska-Markiewicz
Barbara
B
Kocełak
Piotr
P
Janowska
Joanna
J
Semik-Grabarczyk
Elzbieta
E
D000328:Adult; D000735:Androstenedione / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004038:Diet, Reducing; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007249:Inflammation / Q000097:blood* / Q000150:complications; D007328:Insulin / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000178:diet therapy; D011044:Poland; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000178:diet therapy*; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D018709:Statistics, Nonparametric; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D015431:Weight Loss
D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D015850:Interleukin-6; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D012738:Sex Hormone-Binding Globulin; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002784:Cholesterol; D006854:Hydrocortisone